Lalit Kumar

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lalit Kumar
Born
India
Alma materSarojini Naidu Medical College, Agra

Adyar Cancer Institute, Chennai

Royal Postgraduate Medical School
OccupationMedical Oncologist
AwardsPadma Shri
B. C. Roy Award
ICMR Award
Ranbaxy Science Foundation Award
Fulbright fellowship

Lalit Kumar is an Indian oncologist, known to have contributed to the development of low cost medical facilities in Delhi.[1] The Government of India honoured him, in 2014, with the award of Padma Shri, the fourth highest civilian award, for his contributions to the fields of medicine.[2]

Biography[edit]

Cancer cells grow everyday and very fast. So, loss of even a day is a great loss, says Dr. Lalit Kumar.[3]

Kumar is a graduate in medicine from Sarojini Naidu Medical College, Agra.[4] He did his higher studies (DM) at the Adyar Cancer Institute, Chennai and followed it up with a post doctoral fellowship at the Royal Postgraduate Medical School of the Hammersmith Hospital, London. Kumar, a Fulbright scholar,[4] is the Professor and Head of the Medical Oncology department at Dr. B. R. Ambedkar Institute Rotary Cancer Hospital,[5] All India Institute of Medical Sciences (AIIMS), New Delhi[1][6] where he focusses on Multiple Myeloma and Gynaecological malignancies. During his tenure at the AIIMS, Kumar is known to have developed cost effective treatment protocols for sustained bone marrow and stem cell transplantations.[1][4]

Kumar has been honoured by the Indian Academy of Sciences (FASc) and the National Academy of Medical Sciences of India (FAMS) with fellowships.[4][5] He is also a recipient of the Indian Council of Medical Research (ICMR) award and Ranbaxy Science Foundation award.[4] In 2008, the Government of India honoured him with Dr. B. C. Roy Award,[4] the highest award by the Indian government in the medical category.[7] This was followed by another government honour, the Padma Shri when he was included in the Republic Day honours in 2014.[2]

Kumar is a member of the Indo British Health Initiative (IBHI),[8] a foundation promoting scientific collaboration on healthcare between the UK and India.[9] He represents AIIMS in the inter institutional collaborative initiative with Institute of Women's Health (IfWH) of the University College of London (UCL) in the area of gynecological oncology.[10] He is also a member of the Expert Committee to examine the Serious Adverse Events (SAE) of deaths occurring during clinical trials.[11]

Kumar's researches have been documented.[12] Pubfacts, a knowledge repository with PubMed scientific data, has listed over 50 articles by Dr. Lalit Kumar.[13] He also attends international conferences on a regular basis.[14]

See also[edit]

References[edit]

  1. ^ a b c "Drug Today". Drug Today. 2014. Archived from the original on 2014-11-04. Retrieved November 4, 2014.
  2. ^ a b "Padma 2014". Press Information Bureau, Government of India. 25 January 2014. Archived from the original on 8 February 2014. Retrieved October 28, 2014.
  3. ^ "Reminiscences of a Cancer Patient". Cancer Care India. 2014. Retrieved November 4, 2014.
  4. ^ a b c d e f "Cure Panel". Cure Panel. 2014. Retrieved November 4, 2014.
  5. ^ a b "Increb". Increb. 2014. Retrieved November 4, 2014.
  6. ^ "AIIMS listing" (PDF). AIIMS. 2014. Retrieved November 4, 2014.
  7. ^ "BC Roy". Outlook. 2008. Retrieved November 4, 2014.
  8. ^ "IBHI". IBHI. 2014. Retrieved November 4, 2014.
  9. ^ "IBHI Member". IBHI. 2014. Retrieved November 4, 2014.
  10. ^ "University College of London". University College of London. 2014. Retrieved November 4, 2014.
  11. ^ "ISCR" (PDF). ISCR. 2014. Retrieved November 4, 2014.
  12. ^ "CTRI". CTRI. 2014. Retrieved November 4, 2014.
  13. ^ "List of Articles on Pub Facts". Pub Facts. 2014. Retrieved November 4, 2014.
  14. ^ "Ranbaxy". Ranbaxy. 2014. Retrieved November 4, 2014.

External links[edit]